When only responses to TCLs/TCLs + IFNγ were considered, responses were increased in MM PD-1 res samples compared to RCC (p < 0.05), in both melanoma cohorts (regardless of previous anti-PD-1 treatment) compared to OC (p < 0.001) and in SAR compared to OC (p < 0.01) (n = 135, Figure S2B). This evidence concerns the gene IFNG and melanoma.